Ac23 Invitae Ciitizen Data From Cholangiocarcinoma Cohort Youtube Day 3: amanda nottke. Invitae (nyse: nvta), a leading medical genetics company, today announced a partnership with astrazeneca (lse sto nasdaq: azn) to use invitae's ciitizen natural history data in a retrospective and prospective study of patients diagnosed with cholangiocarcinoma, a rare bile duct cancer. this partnership will enable sharing of high quality, patient consented data from the patient community of.
Clinicopathological Data Of The Cholangiocarcinoma Cohort With Complete The data generated by invitae's ciitizen platform is comprehensive, leveraging the hipaa right of access to gather full medical records, longitudinally, from all of the patients' sites of care. The data used in this partnership, collected on behalf of patients with cholangiocarcinoma or their caregivers, is de identified and shared only with their consent, and represents the richest aggregation of real world clinical evidence for patients with cholangiocarcinoma. the data generated by invitae’s ciitizen platform is comprehensive. Medical genetics company invitae announced on thursday that it has inked a collaboration with pharma heavyweight astrazeneca to leverage invitae’s ciitizen genomic and health history data in a retrospective and prospective study of patients diagnosed with the rare bile duct cancer cholangiocarcinoma. First use of ciitizen platform as source of real world data in regulatory filingsan francisco and boston, sept. 20, 2022 (globe newswire) invitae (nyse: nvta) and praxis precision medicines.
Comments are closed.